ArticleFrontiers in cell and developmental biology2025
PARP9 drives the malignant progression of pancreatic cancer cells by regulating apoptosis, DNA damage, and multidrug efflux systems.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Targeted therapy is a potent strategy for the treatment of advanced and metastatic cancers, with pancreatic cancer (PC) being one of the leading causes of cancer-related deaths worldwide. In order to resolve the limitations of existing targeted agents, there is an urgent need to find new targets and therapeutic strategies. Poly (ADP-ribose) polymerase 9 (PARP9) is aberrantly expressed in a variety of tumors. However, its relationship with PC has not been fully investigated. Lysyl oxidase like 2 (LOXL2) is potential therapeutic targets in challenging PC, which contributes to the malignant progression of PC and poor prognosis. Methods: Cell lines with PARP9 knockdown or overexpression were established by lentiviral transfection, while LOXL2 was overexpressed by plasmid, and we validated the effect of PARP9 on apoptosis and DNA damage in PC cells using flow cytometry, comet assay, and western blots. The changes in downstream targets and signaling pathways after PARP9 expression changes were analyzed by RNA sequencing and protein blotting analysis. Finally, the relationship between PARP9 and LOXL2 was analyzed by immunoprecipitation, and the multidrug efflux system was determined by boinformatics analysis and western blots. Results: PARP9 and LOXL2 were highly expressed in PC tissues and were associated with poor prognosis. PARP9 knockdown significantly inhibited the proliferation, invasion, and migration of PC cells, while also promoting apoptosis, increasing DNA damage, and inhibiting multidrug efflux systems. Meanwhile overexpression of LOXL2 reduced apoptosis and DNA damage, and drug sensitivity in PC cells caused by PARP9 knockdown. The therapeutic process of PARP9 in PC may be achieved through the synergistic action of LOXL2 and PI3K/AKT signaling pathway. Conclusion: Our study reveals a potential link between PARP9 and PC, and targeting PARP9 and LOXL2 in monotherapy or combination therapy may provide novel strategies to advanced PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.